亚洲精品1234,久久久久亚洲国产,最新久久免费视频,我要看一级黄,久久久性色精品国产免费观看,中文字幕久久一区二区三区,久草中文网

Home>Latest

Pudong doubles down on innovation in drugs and medical devices

english.pudong.gov.cn Updated:2026-05-07

Shanghai's Pudong New Area is accelerating the rollout of innovative medicines and medical devices, expanding treatment options for patients worldwide.

中國藥谷.png

Zhangjiang · Pharma Valley of China in Pudong New Area, Shanghai. [Photo/WeChat ID: pdnews]

Pudong-based Shenqi Medical Technology Co Ltd recently announced that its self-developed SQ-Kyrin-M? transcatheter mitral valve repair system has received market approval from the National Medical Products Administration (NMPA) of China. The minimally invasive device is designed for patients with severe degenerative mitral regurgitation who are considered at high surgical risk following evaluation.

The product became the eighth innovative medical device approved in Pudong this year, bringing the area's total number of approvals beyond last year's full-year figure.

Progress has also continued in the development of innovative drugs. Pudong-based biopharmaceutical company Henlius Biotech Inc and its partner Organon recently announced that the European Commission (EC) has approved POHERDY? (pertuzumab-dpzb) 420 milligrams/14 milligrams solution for intravenous infusion.

The product is the first and currently the only biosimilar of PERJETA? approved in Europe, and it covers all indications of the reference product. PERJETA? is used in combination with other therapies for the treatment of HER2-positive breast cancer.

According to the company, POHERDY? is also the only pertuzumab biosimilar approved in both the US and European markets, highlighting Henlius' growing global capabilities in biologic drug development and commercialization. Its application for market approval in China has also been accepted for review.